Clinical trials
COVID-19 trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
168 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 93 |
| 2021 | 44 |
| 2022 | 14 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 107 |
| Unknown status | 24 |
| Terminated | 22 |
| Recruiting | 8 |
| Active, not recruiting | 4 |
| Withdrawn | 2 |
| Approved for marketing | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University Hospital, Ghent | 16 |
| Jessa Hospital | 10 |
| Pfizer | 10 |
| Universitair Ziekenhuis Brussel | 9 |
| Universitaire Ziekenhuizen KU Leuven | 8 |
| Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 7 |
| Sciensano | 7 |
| University of Liege | 6 |
| Brugmann University Hospital | 5 |
| AstraZeneca | 4 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| COVID-19 | 168 |
| Severe Acute Respiratory Syndrome | 18 |
| Coronavirus Infections | 17 |
| Pneumonia | 10 |
| Respiratory Tract Infections | 7 |
| Infections | 6 |
| Pneumonia, Viral | 6 |
| Respiratory Distress Syndrome | 6 |
| Virus Diseases | 6 |
| Critical Illness | 5 |
Trials
Showing 1 to 25 of 168. Each trial links to its page on Pharma Observatory.
68 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.